Literature DB >> 3978343

Oral contraception and serious psychiatric illness: absence of an association.

M P Vessey, K McPherson, M Lawless, D Yeates.   

Abstract

The incidence of serious psychiatric illness, as measured by first referral to hospital for specialist advice and treatment, has been investigated among 16,746 women taking part in the Oxford Family Planning Association contraceptive study. Of these women, 9,504 were recruited while using oral contraceptives, 4,144 while using a diaphragm and 3,098 while using an intrauterine device. The results are reassuring with respect to oral contraceptive use. First referral rates per 1000 woman-years of observation in the oral contraceptive, diaphragm, and intrauterine device entry groups were 3.0, 2.6, and 2.8 respectively for non-psychotic psychiatric disorders and 0.46, 0.43 and 0.53 respectively for psychotic disorders. Attempted suicide occurred only 40% as often amongst diaphragm users as amongst users of oral contraceptives or intrauterine devices; this finding presumably reflects the characteristics of women who choose the diaphragm as their birth control method.

Entities:  

Keywords:  Barrier Methods--side effects; Contraception--side effects; Contraceptive Agents, Female--side effects; Contraceptive Agents--side effects; Contraceptive Methods--side effects; Depression; Developed Countries; Diseases; England; Europe; Family Planning; Incidence; Iud--side effects; Measurement; Mental Disorders; Northern Europe; Oral Contraceptives--side effects; Research Methodology; United Kingdom; Vaginal Barrier Methods--side effects; Vaginal Diaphragm--side effects

Mesh:

Substances:

Year:  1985        PMID: 3978343     DOI: 10.1192/bjp.146.1.45

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  1 in total

1.  Mortality among oral contraceptive users: 20 year follow up of women in a cohort study.

Authors:  M P Vessey; L Villard-Mackintosh; K McPherson; D Yeates
Journal:  BMJ       Date:  1989-12-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.